We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

211 hedge funds and large institutions have $3.11B invested in Cytokinetics in 2021 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 97 increasing their positions, 45 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more call options, than puts

Call options by funds: $16.7M | Put options by funds: $5.69M

116% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 45

115% more capital invested

Capital invested by funds: $1.45B → $3.11B (+$1.67B)

92% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 25

60% more funds holding in top 10

Funds holding in top 10: 5 → 8 (+3)

11% more funds holding

Funds holding: 190 → 211 (+21)

2.7% more ownership

Funds ownership: 105.38% → 108.08% (+2.7%)

Holders
211
Holders Change
+21
Holders Change %
+11.05%
% of All Funds
3.69%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.14%
New
48
Increased
97
Reduced
45
Closed
25
Calls
$16.7M
Puts
$5.69M
Net Calls
+$11M
Net Calls Change
+$6.59M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$118M
2
BlackRock
BlackRock
New York
+$47.4M
3
PHS
PFM Health Sciences
California
+$43.4M
4
Franklin Resources
Franklin Resources
California
+$29.4M
5
CAM
Cormorant Asset Management
Massachusetts
+$29.4M

Top Sellers

1
MWNA
Marshall Wace North America
New York
-$32.4M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$14.1M
3
VC
Vivo Capital
California
-$13.9M
4
LGM
Logos Global Management
California
-$11.8M
5
IHAM
Integral Health Asset Management
New York
-$11M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$474M +$47.4M +1,608,545 +14%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$446M +$118M +3,996,325 +47%
Vanguard Group
3
Vanguard Group
Pennsylvania
$190M +$17.3M +588,842 +12%
State Street
4
State Street
Massachusetts
$154M +$1.75M +59,502 +1%
PHS
5
PFM Health Sciences
California
$113M +$43.4M +1,472,689 +87%
DCM
6
Driehaus Capital Management
Illinois
$103M -$6.19M -210,131 -7%
FCM
7
Farallon Capital Management
California
$97.7M -$4.22M -143,225 -5%
WA
8
Wasatch Advisors
Utah
$94.6M +$1.58M +53,725 +2%
PAMS
9
Pictet Asset Management (Switzerland)
Switzerland
$83M +$70.4M +2,390,792 New
BC
10
Boxer Capital
California
$75.1M – – –
RI
11
RTW Investments
New York
$71.5M – – –
DM
12
Deerfield Management
New York
$54.9M +$8.79M +298,675 +24%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$50M +$5.52M +187,626 +16%
AG
14
Artal Group
Luxembourg
$46.5M +$23.6M +800,000 +160%
Wellington Management Group
15
Wellington Management Group
Massachusetts
$37.6M -$4.64M -157,466 -13%
Northern Trust
16
Northern Trust
Illinois
$36.1M +$3.01M +102,360 +11%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$36.1M +$20.1M +681,800 +208%
Franklin Resources
18
Franklin Resources
California
$35.7M +$29.4M +1,000,047 New
LGM
19
Logos Global Management
California
$35.7M -$11.8M -400,000 -29%
CAM
20
Cormorant Asset Management
Massachusetts
$35.7M +$29.4M +1,000,000 New
Goldman Sachs
21
Goldman Sachs
New York
$35.2M +$12.4M +421,962 +75%
Morgan Stanley
22
Morgan Stanley
New York
$30.1M -$2.62M -89,036 -10%
BNP Paribas Asset Management
23
BNP Paribas Asset Management
France
$29.4M -$8.07M -274,057 -25%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$29.3M -$1.68M -57,100 -7%
CC
25
Commodore Capital
New York
$28.5M +$2.72M +92,261 +13%
1
2 3 4 5

CYTK Hedge Fund Activity: Q3 2021 in Review

211 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2021, worth a combined $3.11B — up 115% from $1.45B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new CYTK positions and 25 closed out — a net gain of 23 holders — while 97 added to existing stakes and 45 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $118M. The largest seller was Marshall Wace North America, cutting an estimated $32.4M.

  • 211 institutional investors held Cytokinetics (CYTK) as of Q3 2021, up from 190 in Q2 2021.
  • Funds reported $3.11B of Cytokinetics stock for Q3 2021, up 115% quarter-over-quarter.
  • 48 funds opened new Cytokinetics positions in Q3 2021 and 25 closed out, a net change of +23 holders.
  • The largest Cytokinetics buyer in Q3 2021 was Fidelity Investments, an estimated $118M added.
  • The largest Cytokinetics seller in Q3 2021 was Marshall Wace North America, an estimated $32.4M sold.

Based on aggregated 13F filings for Q3 2021.